Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TYMP | P19971 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | ST6GAL1 | P15907 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6854714 | 0.88 | TYMP (0.48) | L3MBTL1TYMPLMNATHRBMTOR | |
| SCHEMBL5710027 | 0.86 | LMNA (0.51) | L3MBTL1TYMPLMNATHRBMTOR | |
| SCHEMBL5982553 | 0.86 | P2RY2 (0.39) | P2RY2 | |
| SCHEMBL5977400 | 0.80 | P2RY2 (0.39) | TYMPP2RY2 | |
| SCHEMBL6932220 | 0.78 | P2RY6 (0.47) | TYMPP2RY2 | |
| SCHEMBL27543972 | 0.78 | LMNA (0.52) | L3MBTL1LMNATHRBMTORMDM2 | |
| SCHEMBL6932384 | 0.77 | P2RY6 (0.47) | TYMPP2RY2 | |
| SCHEMBL6934529 | 0.75 | P2RY6 (0.49) | TYMPST6GAL1P2RY2 | |
| SCHEMBL7261558 | 0.75 | TYMP (0.39) | TYMP | |
| SCHEMBL7719138 | 0.74 | P2RY6 (0.42) | TYMPP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487855-A2 | METHOD OF USING MODIFIED OLIGONUCLEOTIDES FOR HEPATIC DELIVERY | ISIS Pharmaceuticals, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040142899-A1 | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals | ISIS PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | disclosed |
| US-6753423-B1 | FOR PREFERENTIALLY MODULATED GENE EXPRESSION IN LIVER AND ASSOCIATED TISSUES | ISIS PHARMACEUTICALS, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030191075-A1 | Method of using modified oligonucleotides for hepatic delivery | ISIS PHARMACEUTICALS, INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003072711-A2 | METHOD OF USING MODIFIED OLIGONUCLEOTIDES FOR HEPATIC DELIVERY | ISIS PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| US-6001991-A | NUCLEOTIDE SEQUENCES WHICH HYBRIDIZE TO AND SUPPRESS EXPRESSION OF MULTIDRUG RESISTANCE GENE; FOR PREVENTING OR MODULATING THE DEVELOPMENT OF MULTIDRUG RESISTANCE DURING CHEMOTHERAPEUTIC TREATMENT OR RESENSITIZING TREATED CELLS | ISIS PHARMACEUTICALS INC. (US) | 1999-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142899-A1 | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals | FABP1, RNASE1, RNGTT | L3MBTL1 16/4885TYMP 20/4885LMNA 1279/4885 |
| US-20030191075-A1 | Method of using modified oligonucleotides for hepatic delivery | FABP1, DCLRE1B, SLC10A1 | L3MBTL1 563/4885TYMP 219/4885LMNA 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.